Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

106.96 +0.10 (+0.09%)
Streaming Delayed Price Updated: 9:37 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Abbott Laboratories Stock Gets A Healthy Technical Rating Upgrade
In a welcome move, Abbott Laboratories stock saw its Relative Strength Rating improve from 67 to 73 on Wednesday. 
Via Investor's Business Daily
Peering Into Abbott Laboratories's Recent Short Interest
Via Benzinga
3 Cash Cows to Boost Your Confidence During the February Chill
The market can be a tricky place. Bet on these cash cow stocks to help restore confidence and extract steady returns. 
Via InvestorPlace
The Smartest Dividend Stocks to Buy With $400 Right Now
These stocks reward you during any market environment. 
Via The Motley Fool
Cardiology's Quantum Leap: FDA's Advisory Panel Gives Thumbs Up To Abbott's Minimally Invasive Heart Valve Repair Device
FDA panel confirms support (13-1) for Abbott Laboratories' TriClip TEER system in treating tricuspid regurgitation. Approval decision expected from FDA in 2024. 
Via Benzinga
Exposures Product Safety
FDA Advisors Set To Discuss Abbott's TriClip For Heart Valve Disorder As Questions On Pivotal Trial Loom
FDA to review Abbott's TriClip G4 System for severe tricuspid regurgitation. Circulatory System Devices Panel meeting and insights from the briefing document. 
Via Benzinga
Exposures Product Safety
This Is What Whales Are Betting On Abbott Laboratories
Via Benzinga
Is Abbott Laboratories Stock a Buy Now?
Can Abbott Laboratories be a reliable income stock to hang on to now? 
Via The Motley Fool
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How.
Abbott Labs has an impressive portfolio of nutrition drinks, and its latest addition could help it profit from a new market: people taking prescribed weight loss drugs. 
Via The Motley Fool
3 Groundbreaking Healthcare Stocks to Buy for Robust Gains
Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector. 
Via InvestorPlace
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
There's room for multiple winners in the fast-growing weight-loss market. 
Via The Motley Fool
Abbott Laboratories Stock Getting Closer To Key Technical Benchmark
Abbott Laboratories shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
7 Tremendous Dividend Stocks With Double-Digit 5-Year Growth Rates
When it comes to buying dividend stocks, investors should seek out companies that consistently and repliably grow their payout over time. 
Via InvestorPlace
Looking Into Abbott Laboratories's Recent Short Interest
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Abbott Laboratories
Via Benzinga
Want to Get Richer? Here Are the 3 Best Stocks to Buy Now and Hold Forever
Healthcare is an excellent place to find some tried and true wealth compounders. 
Via The Motley Fool
Healthcare And Life Science Funds And ETFs Performance 2023-2024
Healthcare stocks usually provide a defensive posture to a stock portfolio. 
Via Talk Markets
Topics ETFs
2 Stocks to Buy Near Their 52-Week Highs
It's not too late to invest in these stocks. 
Via The Motley Fool
2 Healthcare Dividend Kings to Buy and Hold Forever
It's going to take a lot to interrupt these companies' streaks. 
Via The Motley Fool
Abbott Faces Lawsuit As Grandmother Questions PediaSure's Height Growth Claims
Abbott Laboratories faces a lawsuit questioning the efficacy of PediaSure Grow & Gain nutrition drinks in promoting height growth. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Could Abbott Labs Be the Next Big Winner in the Billion-Dollar Weight Loss Market?
Abbott Labs is using its well-established strengths to make gains in the weight loss market. 
Via The Motley Fool
7 ‘AgeTech’ Stocks to Profit From the Booming Longevity Market
Aging is an inevitability, as much as we try to deny it. Under this context, these AgeTech stocks may prove quite relevant. 
Via InvestorPlace
Stock Market Continues To Rally; ASML, Netflix, Tesla, Intel Are Big Earnings Movers: Weekly Review
The S&P 500 and Dow Jones hit fresh record highs on Friday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
World's Smallest Brain Stimulation Device For Movement Disorder: FDA Approved Abbott's Liberta RC DBS system
Abbott's Liberta RC DBS system, the world's smallest FDA-approved rechargeable deep brain stimulation device. With only 10 recharges a year, it's compatible with NeuroSphere Virtual Clinic, reducing... 
Via Benzinga
Exposures Product Safety
Stock Market Extends Record Highs, S&P 500 Hits 4,900 On Tech Rally, Microsoft's $3 Trillion Mark: What's Driving Markets Wednesday?
It’s a bullish day on Wall Street, with major U.S. large-cap indices reaching record highs, driven by broad-based rallies in tech-related stocks as investors continue to embrace the AI trade. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript
ABT earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Abbott Laboratories Surpasses Q4 Sales Expectations, Despite Dip In COVID-19 Testing Demand
Abbott Laboratories exceeds expectations with Q4 sales of $10.24B, showcasing resilience despite softer demand for COVID-19 testing. CEO anticipates continued growth in 2024. 
Via Benzinga
Exposures COVID-19
Abbott Labs Skids On Light Earnings Guidance Despite Quarterly Sales Beat
Abbott beat sales expectations and earnings came in light for the fourth quarter. 
Via Investor's Business Daily
Abbott Laboratories Barely Hits Q4 Target With $1.19 EPS
Abbott Laboratories announces Q4 results with $10.24 billion in revenue and an EPS of $1.19. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.